Examines postoperative delirium prevention in older surgical patients, indicating the need for targeted strategies.
Perioperative brain health, encompassing postoperative delirium (POD) and longer-lasting cognitive decline, has become a major priority for patient safety and quality of recovery in older surgical patients. The 2018 unified nomenclature introduced perioperative neurocognitive disorders as an umbrella term spanning pre-existing neurocognitive disorder, POD, delayed neurocognitive recovery, and postoperative neurocognitive disorder. The incidence of POD varies widely, reflecting differences in age, baseline cognition, surgical type, and ascertainment; however, its clinical footprint is consistently substantial, with increased mortality, longer hospitalization, and downstream cognitive deterioration. Electroencephalography (EEG)-guided anesthesia trials have yielded mixed results, favoring its integration with hemodynamic optimization and medication stewardship. Screening uptake remains < 10% in many settings, limiting the ability to provide scalable and equitable brain care. Current prevention standards prioritize multicomponent, non-pharmacological bundles such as mobilization, reorientation/cognitive stimulation, sleep promotion, sensory optimization, hydration, nutrition, oxygen delivery, and prompt management of precipitating factors. Nonetheless, translation to “precision prevention” is constrained by three gaps: low implementation of recommended screening pathways, heterogeneity and limited transportability of prognostic models, and an under-operationalized vulnerability domain in which frailty and malnutrition lack standardized tools, cut-offs, and linked interventions. Biomarkers and perioperative physiology including EEG suppression patterns and individualized perfusion targets are biologically coherent adjuncts for risk refinement; however, current evidence supports their use as additive stratifiers within bundles rather than stand-alone gatekeepers. Next-generation perioperative brain health studies should standardize vulnerability phenotyping, integrate evidence-based selective monitoring and biomarker-informed refinement, and embed these elements into scalable workflows that convert guidelines into practical bedside actions.
No takes yet. Share an insight, caveat, or question.
Kim et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: